Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 with or without cetrelimab versus BCG in BCG-naive high-risk non-muscle invasive bladder cancer
NL-OMON56283Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma (TCC) comparing TAR-200 + cetrelimab, Intravesical BCG and TAR-200 alone (3 arms). Primary endpoint: Event-free survival. Started Nov 2023; status: recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON56283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56283.